BTIG Research Reaffirms “Buy” Rating for Integra Lifesciences (IART)

BTIG Research reaffirmed their buy rating on shares of Integra Lifesciences (NASDAQ:IART) in a research report report published on Wednesday, September 12th. BTIG Research currently has a $69.00 price objective on the life sciences company’s stock.

IART has been the subject of several other reports. Oppenheimer reaffirmed a buy rating and set a $74.00 target price on shares of Integra Lifesciences in a research report on Wednesday, July 25th. BidaskClub raised Integra Lifesciences from a hold rating to a buy rating in a research report on Thursday, August 2nd. Cantor Fitzgerald reaffirmed a hold rating and set a $59.00 target price on shares of Integra Lifesciences in a research report on Tuesday, June 12th. JPMorgan Chase & Co. lifted their price objective on Integra Lifesciences from $57.00 to $65.00 and gave the stock a neutral rating in a research report on Tuesday, May 22nd. Finally, Bank of America lowered Integra Lifesciences from a neutral rating to an underperform rating in a research report on Tuesday, August 7th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. Integra Lifesciences has an average rating of Hold and a consensus target price of $61.38.

NASDAQ:IART traded down $0.28 during trading hours on Wednesday, hitting $61.42. 452,715 shares of the company were exchanged, compared to its average volume of 728,293. The firm has a market cap of $5.61 billion, a P/E ratio of 31.66, a P/E/G ratio of 2.03 and a beta of 0.57. The company has a quick ratio of 2.27, a current ratio of 3.52 and a debt-to-equity ratio of 1.10. Integra Lifesciences has a one year low of $41.51 and a one year high of $67.50.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.60. The business had revenue of $366.20 million during the quarter, compared to analyst estimates of $368.08 million. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. Integra Lifesciences’s revenue for the quarter was up 29.8% compared to the same quarter last year. During the same period last year, the company earned $0.45 EPS. As a group, equities research analysts expect that Integra Lifesciences will post 2.4 EPS for the current year.

In other news, VP Glenn Coleman sold 8,916 shares of the firm’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $63.00, for a total value of $561,708.00. Following the completion of the sale, the vice president now directly owns 16,795 shares in the company, valued at approximately $1,058,085. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey Mosebrook sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the sale, the insider now owns 3,085 shares of the company’s stock, valued at $192,565.70. The disclosure for this sale can be found here. Over the last three months, insiders sold 270,892 shares of company stock valued at $17,280,372. Corporate insiders own 5.10% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Paloma Partners Management Co acquired a new stake in shares of Integra Lifesciences in the 2nd quarter valued at about $12,012,000. GSA Capital Partners LLP acquired a new position in Integra Lifesciences during the 2nd quarter valued at about $538,000. Bank of Montreal Can boosted its stake in Integra Lifesciences by 55.8% during the 2nd quarter. Bank of Montreal Can now owns 16,018 shares of the life sciences company’s stock valued at $1,031,000 after purchasing an additional 5,739 shares during the last quarter. Sei Investments Co. boosted its stake in Integra Lifesciences by 12.1% during the 2nd quarter. Sei Investments Co. now owns 179,756 shares of the life sciences company’s stock valued at $11,578,000 after purchasing an additional 19,377 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Integra Lifesciences by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 494,735 shares of the life sciences company’s stock valued at $27,379,000 after purchasing an additional 10,388 shares during the last quarter. Institutional investors own 84.41% of the company’s stock.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: Diversification in Investing

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply